No Data
No Data
No Data
This state-owned enterprise succeeded in IPO relying on "monkey"!
The STAR Market is about to welcome a new listing. According to UBS, Yinosi (688710.SH) completed its subscription on August 23rd and will be listed on the STAR Market soon. Haitong Securities is the sponsoring institution. Yinosi is a biomedical CRO company, ranking third in market share in the domestic non-clinical safety evaluation segment, behind Wuxi AppTec and Joinn Laboratories. When it comes to CXOs, many investors will think of Glan as their first reaction. The ups and downs of the CXO industry in recent years have left many people feeling regretful. Everyone involved in it cannot escape the industry's cycles. Yinosi has experienced high growth in the industry's wave.
Yinuo Si (688710.SH): After the callback, the final online subscription rate is 0.0486%.
YinuoSi (688710.SH) announced that after the recall mechanism was activated, the final number of offline issuances was 1691....
A-share subscription | Yinosi (688710.SH) starts subscription, ranking the top three in the domestic non-clinical safety evaluation subdivision market share.
On August 23rd, Yinuosi (688710.SH) started the subscription, with an issue price of 19.06 yuan per share and a maximum subscription limit of 0.008 million shares, with a PE ratio of 15.4 times. It belongs to the STAR Market of the Shanghai Stock Exchange, with Haitong Securities as the sponsor and lead underwriter.
Yinuosi (688710.SH): IPO issue price of 19.06 yuan/share, subscription on August 23rd.
On August 21st, Ganlonghui announced that based on the preliminary inquiry results, the issuer and the sponsor (main underwriter) comprehensively evaluated the reasonable investment value of the company, the valuation level of listed companies in the same industry, and the valuation level of secondary market in the industry, considering the effective subscription multiple of offline investors, market conditions, fundraising needs, and underwriting risks. After consultation, the issue price for this offering is determined to be RMB 19.06 per share, and there will be no cumulative tender offer for offline offering. Investors are requested to apply for online and offline subscription at this price on August 23, 2024 (T day) without payment.
Shanghai InnoStar Bio-tech Gets Regulatory Nod for Shanghai IPO
Biomedical CRO company InnoStar (688710.SH) plans to publicly issue 35.2449 million shares for non-clinical research services.
Yinuo Si (688710.SH) has released its first public offering of stocks and intends to list on the STAR market. The company...
No Data